A Cancer Research UK Phase II Proof of Principle Trial of the Activity of the Intravenous PARP-1 Inhibitor, AG-014699, in Known Carriers of a BRCA 1 or BRCA 2 Mutation With Locally Advanced or Metastatic Breast or Advanced Ovarian Cancer.

Trial Profile

A Cancer Research UK Phase II Proof of Principle Trial of the Activity of the Intravenous PARP-1 Inhibitor, AG-014699, in Known Carriers of a BRCA 1 or BRCA 2 Mutation With Locally Advanced or Metastatic Breast or Advanced Ovarian Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2016

At a glance

  • Drugs Rucaparib (Primary)
  • Indications Advanced breast cancer; Fallopian tube cancer; Ovarian cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PARP-BRCA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Mar 2016 Results published in the British Journal of Cancer
    • 04 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top